PLUVICTO (lutetium Lu-177 vipivotide tetraxetan)
METASTATIC PROSTATE CARCINOMA·+1
ADVANCED ACCELE
Indication
Prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer
Prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer is an advanced, lethal malignancy of the male genitourinary system that has disseminated beyond the prostate to distant sites such as bones, lymph nodes, or visceral organs. Read more about Prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer
3 drugs 3 manufacturers
Drugs that treat it
Common Prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer therapies.
PLUVICTO (lutetium Lu-177 vipivotide tetraxetan)
METASTATIC PROSTATE CARCINOMA·+1
Novartis Pharmaceuticals
PLUVICTO (lutetium Lu-177 vipivotide tetraxetan)
METASTATIC PROSTATE CARCINOMA·+1
Novartis Pharmaceuticals
Filter & compare in the drug finder →Opens the drug finder with Prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonProstate-specific membrane antigen-positive metastatic castration-resistant prostate cancer is an advanced, lethal malignancy of the male genitourinary system that has disseminated beyond the prostate to distant sites such as bones, lymph nodes, or visceral organs.
It is clinically defined by disease progression—evidenced by rising serum prostate-specific antigen levels or radiological tumor growth—despite achieving medical or surgical castrate levels of serum testosterone.
The condition is further characterized by the marked cell-surface overexpression of prostate-specific membrane antigen, a transmembrane glycoprotein typically identified via diagnostic positron emission tomography imaging.
- pluvicto.com
Prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer is an advanced, lethal malignancy of the male genitourinary system that has disseminated beyond the prostate to distant sites such as bones, lymph nodes, or visceral organs
- asco.org
Prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer is an advanced, lethal malignancy of the male genitourinary system that has disseminated beyond the prostate to distant sites such as bones, lymph nodes, or visceral organs The condition is further characterized by the marked cell-surface overexpression of prostate-specific membrane antigen, a transmembrane glycoprotein typically identified via diagnostic positron emission tomography imaging
- mayoclinic.org
Prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer is an advanced, lethal malignancy of the male genitourinary system that has disseminated beyond the prostate to distant sites such as bones, lymph nodes, or visceral organs
- mayoclinic.org
It is clinically defined by disease progression—evidenced by rising serum prostate-specific antigen levels or radiological tumor growth—despite achieving medical or surgical castrate levels of serum testosterone
- multivu.com
It is clinically defined by disease progression—evidenced by rising serum prostate-specific antigen levels or radiological tumor growth—despite achieving medical or surgical castrate levels of serum testosterone The condition is further characterized by the marked cell-surface overexpression of prostate-specific membrane antigen, a transmembrane glycoprotein typically identified via diagnostic positron emission tomography imaging
- nih.gov
It is clinically defined by disease progression—evidenced by rising serum prostate-specific antigen levels or radiological tumor growth—despite achieving medical or surgical castrate levels of serum testosterone
- nih.gov
The condition is further characterized by the marked cell-surface overexpression of prostate-specific membrane antigen, a transmembrane glycoprotein typically identified via diagnostic positron emission tomography imaging
Personalize your experience
Follow Prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.